U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H19N3O5S.3H2O
Molecular Weight 419.45
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Amoxicillin

SMILES

O.O.O.CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=C(O)C=C3)C(=O)N2[C@H]1C(O)=O

InChI

InChIKey=MQXQVCLAUDMCEF-CWLIKTDRSA-N
InChI=1S/C16H19N3O5S.3H2O/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7;;;/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24);3*1H2/t9-,10-,11+,14-;;;/m1.../s1

HIDE SMILES / InChI

Description

Amoxicillin is one of the widely prescribed antibacterial agents, which was discovered by scientists at Beecham Research Laboratories in 1972. In the US GlaxoSmithKline markets it under the original brand name Amoxil. It is the first line treatment for middle ear infections. It is also used for strep throat, pneumonia, skin infections, and urinary tract infections it is taken by mouth. Amoxicillin inhibits the third and final stage of bacterial cell wall synthesis by preferentially binding to specific penicillin-binding proteins (PBPs) that are located inside the bacterial cell wall. This results in a formation of defective cell wall and a cell death. Common side effects include nausea and rash. It may also increase the risk of yeast infections and, when used in combination with clavulanic acid, diarrhea. It should not be used in those who are allergic to penicillin.

CNS Activity

Originator

Approval Year

1973
95
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

1980
Curative
Approved
8583
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

1980
Curative
Approved
8583
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

1980
Curative
Approved
8583
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

1980
Curative
Approved
8583
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

1980
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
11.8 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/836010/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXICILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
37.6 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/836010/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXICILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.5 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/836010/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXICILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000medr.pdf
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000medr.pdf
Disc. AE: Pharyngolaryngeal pain...
Other AEs: Nausea, Pharyngotonsillitis...
AEs leading to
discontinuation/dose reduction:
Pharyngolaryngeal pain (severe, 0.6%)
Other AEs:
Nausea (1.5%)
Pharyngotonsillitis (0.9%)
Vulvovaginal candidiasis (0.9%)
Headache (0.7%)
Diarrhea (0.5%)
Abdominal pain (0.5%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000medr.pdf
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 0.5%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000medr.pdf
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000medr.pdf
Diarrhea 0.5%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000medr.pdf
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000medr.pdf
Headache 0.7%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000medr.pdf
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000medr.pdf
Pharyngotonsillitis 0.9%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000medr.pdf
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000medr.pdf
Vulvovaginal candidiasis 0.9%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000medr.pdf
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000medr.pdf
Nausea 1.5%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000medr.pdf
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000medr.pdf
Pharyngolaryngeal pain severe, 0.6%
Disc. AE
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000medr.pdf
unhealthy, > 12 years
Health Status: unhealthy
Age Group: > 12 years
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000medr.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252
inhibitor
2438
inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP3A5
136

CYP2C8
1057

BSEP
550

CYP2A6
879

PEPT1
27

PEPT2
13

OAT1
725

CYP2C19
2057

MRP2
499

P-gp
1741

OATP1B1
1079

CYP2J2
33

CYP2E1
1060

BCRP
910

OATP1B3
961

MRP3
246

CYP19A1
429

CYP1A2
2153

OATP2B1
157

ABCB6
3

MRP4
290
OCT2
434

chicken BCRP
3

OAT1
395

chicken P-gp
3

OAT3
391

PEPT1
60

OATP1B1
503

PEPT2
37

OATP2B1
122

OATP1B3
435

OCT1
393
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2J2
36
 inconclusive [IC50 50 uM]
CYP1A2
2333
 no [IC50 >10 uM]
CYP2A6
911
 no [IC50 >10 uM]
CYP2C19
2141
 no [IC50 >10 uM]
CYP2E1
1146
 no [IC50 >10 uM]
BSEP
554
 no [IC50 >133 uM]
MRP2
625
 no [IC50 >133 uM]
MRP3
326
 no [IC50 >133 uM]
MRP4
345
 no [IC50 >133 uM]
ABCB6
3
 no
BCRP
985
 no
CYP19A1
430
 no
CYP2C9
2497
 no
CYP2D6
2546
 no
CYP3A4
2633
 no
CYP3A5
201
 no
P-gp
1932
 no
P-gp
1932
 no
OAT1
730
 unlikely [Ki 11000 uM]
PEPT1
29
 unlikely [Ki 66200 uM]
PEPT2
17
 unlikely [Ki 733 uM]
CYP2C8
1117
 yes [IC50 0.83 uM]
OATP1B3
970
 yes [IC50 28.9 uM]
OATP1B1
1095
 yes [IC50 36.2 uM]
OATP2B1
162
 yes [IC50 56.6 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
OATP1B1
503
 likely
OCT1
393
 likely
OCT2
434
 likely
OAT1
395
 no
OATP1B3
435
 no
OATP2B1
122
 no
chicken BCRP
3
 no
chicken P-gp
3
 no
PEPT2
37
 yes [Km 1040 uM]
OAT3
391
 yes [Km 161.4 uM]
PEPT1
60
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B2-0028
http://www.3bsc.com/index/pro_info.php?id=19384
Aaron Chemicals
AR006UMZ
http://www.aaronchem.com/26787-78-0
abcr GmbH
AB439985
http://www.abcr.com/shop/en/AB439985
AbMole Bioscience
M4095
http://www.abmole.com/products/notoginsenoside-fe.html
Achemtek
0104-023910
http://www.achemtek.com/26787-78-0
Acorn PharmaTech
ACN-044355
http://www.acornpharmatech.com/
Acros Organics
AC455140010
https://www.fishersci.com/shop/products/amoxicillin-96-acros-organics-2/AC455140010
Acros Organics
AC455140050
https://www.fishersci.com/shop/products/amoxicillin-96-acros-organics-1/AC455140050
Acros Organics
AC455140250
https://www.fishersci.com/shop/products/amoxicillin-96-acros-organics/AC455140250
Alsachim
723
http://www.alsachim.com/product-C2651-glo.bal-view.html
Aurora Fine Chemicals LLC
A13.142.375
http://online.aurorafinechemicals.com/info?ID=A13.142.375
Aurum Pharmatech LLC
NE41275
http://www.Aurumpharmatech.com/Product/ProductDetails/NE41275
AvaChem Scientific
2773A
http://www.avachem.com/productSearch.asp?2773A
BioCrick
BCC4625
http://www.biocrick.com/Amoxicillin-BCC4625.html
BLD Pharm
BD233963
http://www.bldpharm.com/products/26787-78-0.html
Boerchem
BC204303
http://www.boerchem.com/?product_34374.html
Chem Scene
CS-2612
http://www.chemscene.com/26787-78-0.html
ChemMol
30102056
http://www.chemmol.com/chemmol/30102056.html
ChemMol
44001791
http://www.chemmol.com/chemmol/44001791.html
ChemMol
99055597
http://www.chemmol.com/chemmol/99055597.html
Chemspace
CSSB00000693552
https://chem-space.com/CSSB00000693552
CSNpharm
CSN13145
https://www.csnpharm.com/products/amoxicillin.html
eNovation Chemicals
D673782
https://www.enovationchem.com/ProductDetails.asp?ProductID=D673782
eNovation Chemicals
D764547
https://www.enovationchem.com/ProductDetails.asp?ProductID=D764547
eNovation Chemicals
D783616
https://www.enovationchem.com/ProductDetails.asp?ProductID=D783616
Hairui
HR130838
http://www.hairuichem.com/en/product/61336-70-7.html
iChemical
EBD2203797
http://www.ichemical.com/products/26787-78-0.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network
LN00239840
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00239840
mcule
MCULE-5710225015
https://mcule.com/MCULE-5710225015/
MedChem Express
HY-B0467A
https://www.medchemexpress.com/amoxicillin.html
Selleck Chemicals
S3015
http://www.selleckchem.com/products/amoxicillin-amoxycillin.html
Sigma-Aldrich
A8523_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/a8523?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule
S584747
https://www.smolecule.com/products/s584747
THE BioTek
bt-298733
https://www.thebiotek.com/product/others/bt-298733
Yuhao Chemical
LQ4576
http://www.chemyuhao.com/26787-78-0.html
PubMed

PubMed

TitleDatePubMed
[Acute myocardial infarction after anaphylactic reaction to amoxicillin].
1999 Aug
[Amoxicillin caused aseptic meningoencephalitis].
1999 Jan 20
Acute interstitial nephritis following amoxicillin overdose.
1999 Jun
[Cerebral and renal toxicity of acyclovir in a patient treated for meningoencephalitis].
1999 Nov
[Acute renal failure after amoxicillin crystallization].
2000 Apr 8
Omeprazole-induced delirium.
2000 Jan
[Intrahepatic cholestasis induced by amoxicillin alone].
2000 May
Adverse reaction to amoxicillin: a case report.
2000 Sep-Oct
Comparison of amoxicillin and azithromycin in the prevention of recurrent acute otitis media.
2001 Apr 6
[Eradication therapy of Helicobacter pylori infection].
2001 Feb
[The history of Helicobacter pylori].
2001 Feb
Cefprozil versus high-dose amoxicillin/clavulanate in children with acute otitis media.
2001 Feb
Differentiation between reinfection and recrudescence of helicobacter pylori strains using PCR-based restriction fragment length polymorphism analysis.
2001 Feb
The effect of postsurgical antibiotics on the healing of intrabony defects following treatment with enamel matrix proteins.
2001 Feb
[A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment].
2001 Feb
[Usefulness of new triple therapy containing PPI].
2001 Feb
[Selection of antibiotics and planning of eradication for H. pylori infection].
2001 Feb
[Recent guidelines for the management of Helicobacter pylori infection].
2001 Feb
Free radical production by antibiotic-killed bacteria in the guinea pig middle ear.
2001 Feb
Antibiotic-resistance patterns of Helicobacter pylori in Croatia: cohort study.
2001 Feb
Definite streptococcus bovis endocarditis: characteristics in 20 patients.
2001 Jan
[Prevalence and treatment of Helicobacter pylori in gastro-duodenal ulcers. An experience in Liege].
2001 Jan
Antibiotic susceptibilities of Helicobacter pylori.
2001 Jan
A prospective study of antibiotic use and associated infections in young children.
2001 Jan
[Dilated cardiomyopathy and panuveitis as presenting symptoms of Lyme disease. General review of one case].
2001 Jan
High amoxycillin resistance in Helicobacter pylori isolated from gastritis and peptic ulcer patients in western Nigeria.
2001 Jan
A multidisciplinary approach to the diagnosis and treatment of early-onset periodontitis: a case report.
2001 Jan
Potential for milk containing penicillin G or amoxicillin to cause residues in calves.
2001 Jan
A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China.
2001 Jan
Cause of high variability in drug dissolution testing and its impact on setting tolerances.
2001 Jan
Clinical onset of the Crohn's disease after eradication therapy of Helicobacter pylori infection. Does Helicobacter pylori infection interact with natural history of inflammatory bowel diseases?
2001 Jan-Feb
Standard case management of pneumonia in hospitalized children in Uruguay, 1997 to 1998.
2001 Mar
Osseintegration following treatment of peri-implantitis and replacement of implant components. An experimental study in the dog.
2001 Mar
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
2001 Mar
Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. ORACLE Collaborative Group.
2001 Mar 31
Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. ORACLE Collaborative Group.
2001 Mar 31
Prospective evaluation of the impact of amoxicillin, clarithromycin and their combination on human gastrointestinal colonization by Candida species.
2001 May-Jun
Patents

Patents

JP2007031359A
12
JP2007063489A
3
JP2010507658A
34
JP5364923B2
3
JPH0278945A
3
JPH0665215A
30
JPS5511511A
3
JPS56131525A
3
JPS572293A
3
JPS5746988A
3

Sample Use Guides

In Vivo Use Guide
In adults, 750-1750 mg/day in divided doses every 8-12 hours. In Pediatric Patients > 3 Months of Age, 20-45 mg/kg/day in divided doses every 8-12 hours. Treatment of gonorrhea is 3 grams as a single oral dose. The upper dose for neonates and infants ≤ 3 months is 30 mg/kg/day divided every 12 hours. Dosing for H. pylori Infection: Triple therapy: 1 gram AMOXIL, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Dual therapy: 1 gram AMOXIL and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
AMOXICILLIN TRIHYDRATE
EP   GREEN BOOK   MART.   MI   VANDF   WHO-DD   WHO-IP  
Preferred Name English
Amoxicillin
USAN  
Official Name English
Amoxicillin trihydrate [WHO-DD]
Common Name English
AMOXICILLIN TRIHYDRATE [MI]
Common Name English
AMOXICILLIN [ORANGE BOOK]
Common Name English
TRIMOX
Brand Name English
AMOXYCILLIN TRIHYDRATE
Common Name English
AMOXICILLIN [USP-RS]
Common Name English
AMOXICILLIN TRIHYDRATE [WHO-IP]
Common Name English
PROMOXIL
Common Name English
ATOKSILIN
Common Name English
AMOXICILLIN TRIHYDRATE [VANDF]
Common Name English
CLAVULOX COMPONENT AMOXICILLIN TRIHYDRATE
Common Name English
REMOXIL
Common Name English
LARGOPEN
Common Name English
TALICIA COMPONENT AMOXICILLIN
Brand Name English
AMOXICILLINUM TRIHYDRICUM [WHO-IP LATIN]
Common Name English
UTIMOX
Brand Name English
AMOXICILLIN [USP MONOGRAPH]
Common Name English
AMOXICILLIN (AS TRIHYDRATE)
Common Name English
AUGMENTIN COMPONENT AMOXICILLIN
Brand Name English
POLYMOX
Brand Name English
AMOXICILLIN [USP IMPURITY]
Common Name English
DEMOKSIL
Common Name English
DISPERMOX
Brand Name English
AMOXICILLIN [USAN]
Common Name English
4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 6-((AMINO(4-HYDROXYPHENYL)ACETYL)AMINO)-3,3-DIMETHYL-7-OXO-, TRIHYDRATE(2S-(2.ALPHA.,5.ALPHA.,6.BETA.(S*)))-
Common Name English
PREVPAC COMPONENT AMOXICILLIN
Common Name English
AMOXICILLIN TRIHYDRATE [GREEN BOOK]
Common Name English
AMOXICILLIN TRIHYDRATE [MART.]
Common Name English
MOXATAG
Brand Name English
BRL-2333
Code English
MOKSILIN
Common Name English
AMOXICILLIN HYDRATE
JAN  
Common Name English
AMOXICILLIN HYDRATE [JAN]
Common Name English
DAMOXY
Common Name English
LAROTID
Brand Name English
TOPRAMOXIN
Common Name English
AMOXICILLIN TRIHYDRATE [EP MONOGRAPH]
Common Name English
AMOXIL
Brand Name English
AMOXYKE
Common Name English
WYMOX
Brand Name English
(2S,5R,6R)-6-((R)-(-)-2-AMINO-2-(P-HYDROXYPHENYL)ACETAMIDO)-3,3-DIMETHYL-7-OXO-4-THIA-1-AZABICYCL(3.2.0)HEPTANE-2-CARBOXYLIC ACID TRIHYDRATE
Common Name English
AMOXICILLIN [VANDF]
Common Name English
BRL 2333
Code English
Classification Tree Code System Code
WHO-ATC A02BD06
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
CFR 21 CFR 520.88
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-ATC A02BD07
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-VATC QA02BD07
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 6.2.1 (AMO/CLA)
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-ATC J01CR02
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-VATC QA02BD01
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
NCI_THESAURUS C1500
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
CFR 21 CFR 520.88E
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-VATC QA02BD04
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
CFR 21 CFR 520.88B
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-ATC A02BD03
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
CFR 21 CFR 526.88
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-VATC QA02BD05
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-VATC QJ01CA04
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-ATC A02BD10
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 6.2.1
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
CFR 21 CFR 520.88H
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-ATC A02BD05
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-ATC J01CA04
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-VATC QJ01CR02
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
CFR 21 CFR 520.88C
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-ATC A02BD04
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
NDF-RT N0000175497
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-ATC A02BD11
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
CFR 21 CFR 520.88F
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-VATC QG51AA03
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-VATC QA02BD03
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
CFR 21 CFR 520.88A
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
LIVERTOX NBK547854
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
CFR 21 CFR 520.88G
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-VATC QA02BD06
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-VATC QJ51CR02
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
CFR 21 CFR 556.38
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
CFR 21 CFR 522.88
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
WHO-ATC A02BD01
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
CFR 21 CFR 520.88D
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
Code System Code Type Description
RXCUI
723
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
ALTERNATIVE
CHEBI
51254
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
MESH
D000658
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
SMS_ID
100000092629
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
LACTMED
Amoxicillin and Clavulanic Acid
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
LACTMED
Amoxicillin
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
DRUG BANK
DB01060
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
RS_ITEM_NUM
1031503
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
EPA CompTox
DTXSID2022599
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
DAILYMED
804826J2HU
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
ChEMBL
CHEMBL1082
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
NCI_THESAURUS
C237
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
MERCK INDEX
m1844
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY Merck Index
WHO INTERNATIONAL PHARMACOPEIA
AMOXICILLIN
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY Description: A white or almost white, crystalline powder; odourless. Solubility: Slightly soluble in water and methanol R; very slightly soluble in ethanol (~750 g/l) TS, ether R, and fatty oils; soluble in dilute acids and dilute solutions of alkali hydroxides. Category: Antibacterial drug. Storage: Amoxicillin trihydrate should be kept in a tightly closed container. Requirement: Amoxicillin trihydrate contains not less than 95.0% and not more than the equivalent of 102.0% of C16H19N3O5S, calculated with reference to the anhydrous substance.
CAS
61336-70-7
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
FDA UNII
804826J2HU
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
EVMPD
SUB00504MIG
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
WIKIPEDIA
AMOXICILLIN
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
PUBCHEM
62883
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
RXCUI
133008
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
DRUG CENTRAL
192
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
CHEBI
2676
Created by admin on Mon Mar 31 18:25:09 GMT 2025 , Edited by admin on Mon Mar 31 18:25:09 GMT 2025
PRIMARY
SUBSTANCE RECORD
Structure of Amoxicillin
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966